Clinical significance of mitochondrial DNA content in acute promyelocytic leukaemia

Diego A. Pereira-Martins, Juan L. Coelho-Silva, Isabel Weinhäuser, Pedro L. Franca-Neto, Douglas R. Silveira, César Ortiz, Amanda Moreira-Aguiar, Marinus M. Lima, Luisa C. Koury, Raul A. de Melo, Ana B. Glória, Evandro M Fagundes, Bruno K. Lino, Katia Pagnano, Rosane Bittencourt, Elenaide Nunes, Fabiola Traina, Lorena Figueiredo-Pontes, Armand Keating, Martin S. TallmanRaul C. Ribeiro, Richard Dilon, Arnold Ganser, Miguel A. Sanz, Nancy Berliner, Peter Valk, Bob Löwenberg, Tiziana Ottone, Nelida I. Noguera, Maria T. Voso, Francesca Paoloni, Paola Fazi, Emanuele Ammatuna, Gerwin Huls, Jan Jacob Schuringa, Eduardo M. Rego, Antonio R. Lucena-Araujo*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Scopus)
7 Downloads (Pure)

Abstract

Although a growing body of evidence demonstrates that altered mtDNA content (mtDNAc) has clinical implications in several types of solid tumours, its prognostic relevance in acute promyelocytic leukaemia (APL) patients remains largely unknown. Here, we show that patients with higher-than-normal mtDNAc had better outcomes regardless of tumour burden. These results were more evident in patients with low-risk of relapse. The multivariate Cox proportional hazard model demonstrated that high mtDNAc was independently associated with a decreased cumulative incidence of relapse. Altogether, our data highlights the possible role of mitochondrial metabolism in APL patients treated with ATRA.

Original languageEnglish
Pages (from-to)170-174
Number of pages5
JournalBritish Journal of Haematology
Volume200
Issue number2
DOIs
Publication statusE-pub ahead of print - 20 Oct 2022

Bibliographical note

Funding Information:
This investigation was supported by (CNPq; grant # 303479/2018‐3) and (FAPESP, Grant #2013/08135‐2). D.A.P.M. (Grant #2017/23117‐1), J.L.C.‐S. (Grant #2016/23191‐4) and I.W. (Grant #2015/09228‐0) received a fellowship from FAPESP. I.W and D.A.P‐M were sponsored by the Abel Tasman Talent Program of the Graduate School of Medical Sciences of the University of Groningen/University Medical Center Groningen, The Netherlands. Conselho Nacional de Desenvolvimento Científico e Tecnológico Fundação de Amparo à Pesquisa do Estado de São Paulo

Funding information
Conselho Nacional de Desenvolvimento
Científico e Tecnológico, Grant/Award
Number: 303479/2018-3; Fundação de
Amparo à Pesquisa do Estado de São Paulo,
Grant/Award Number: 2013/08135-2,
2015/09228-0, 2016/23191-4 and 2017/23117-1

Publisher Copyright:
© 2022 British Society for Haematology and John Wiley & Sons Ltd.

Fingerprint

Dive into the research topics of 'Clinical significance of mitochondrial DNA content in acute promyelocytic leukaemia'. Together they form a unique fingerprint.

Cite this